Tenax Therapeutics Inc. [NASDAQ: TENX] stock went on an upward path that rose over 22.96% on Friday, amounting to a one-week price decrease of less than -15.95%. The company report on February 15, 2023 that TENX: New Funding Puts Wind in the Sails.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
By John Vandermosten, CFA.
Over the last 12 months, TENX stock dropped by -95.15%. The one-year Tenax Therapeutics Inc. stock forecast points to a potential upside of 99.08. The average equity rating for TENX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $4.30 million, with 26.33 million shares outstanding and 1.83 million shares in the current float. Compared to the average trading volume of 1.94M shares, TENX stock reached a trading volume of 27526805 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Tenax Therapeutics Inc. [TENX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TENX shares is $62.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TENX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Tenax Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2017. While these analysts kept the previous recommendation, MLV & Co raised their target price to Buy. The new note on the price target was released on December 16, 2014, representing the official price target for Tenax Therapeutics Inc. stock. Previously, the target price had yet another raise to $12, while WallachBeth analysts kept a Buy rating on TENX stock.
The Average True Range (ATR) for Tenax Therapeutics Inc. is set at 0.17 The Price to Book ratio for the last quarter was 3.80.
TENX Stock Performance Analysis:
Tenax Therapeutics Inc. [TENX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.95. With this latest performance, TENX shares dropped by -57.16% in over the last four-week period, additionally sinking by -86.27% over the last 6 months – not to mention a drop of -95.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TENX stock in for the last two-week period is set at 29.93, with the RSI for the last a single of trading hit 30.72, and the three-weeks RSI is set at 31.77 for Tenax Therapeutics Inc. [TENX]. The present Moving Average for the last 50 days of trading for this stock 1.5889, while it was recorded at 0.5767 for the last single week of trading, and 4.3029 for the last 200 days.
Insight into Tenax Therapeutics Inc. Fundamentals:
Return on Equity for this stock declined to -732.21, with Return on Assets sitting at -505.01.
Tenax Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.50 and a Current Ratio set at 6.50.
Tenax Therapeutics Inc. [TENX] Insider Position Details
There are presently around $2 million, or 16.30% of TENX stock, in the hands of institutional investors. The top three institutional holders of TENX stocks are: GOFEN & GLOSSBERG LLC /IL/ with ownership of 3,819,170, which is approximately 1899.995% of the company’s market cap and around 9.10% of the total institutional ownership; ACADIAN ASSET MANAGEMENT LLC, holding 60,500 shares of the stock with an approximate value of $34000.0 in TENX stocks shares; and BLACKROCK INC., currently with $14000.0 in TENX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Tenax Therapeutics Inc. stocks held by institutional investors increased at the end of Monday and at the time of the Monday reporting period, where 6 institutional holders increased their position in Tenax Therapeutics Inc. [NASDAQ:TENX] by around 3,699,468 shares. Additionally, 11 investors decreased positions by around 123,053 shares, while 8 investors held positions by with 118,132 shares. The mentioned changes placed institutional holdings at 3,940,653 shares, according to the latest SEC report filing. TENX stock had 1 new institutional investments in for a total of 60,500 shares, while 8 institutional investors sold positions of 109,131 shares during the same period.